(Sharecast News) - Sanofi's stock was in the red on Monday after the pharma group gave two disappointing updates regarding its tolebrutinib treatment for multiple sclerosis.
Firstly, the company said results from a phase 3 study showed that tolebrutinib did not meet its primary endpoint in delaying the time to onset...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE